AUTHORS

Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for theStreet.com Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (MTAEF.org).
Email Bruce Kamich

Recent Articles By The Author

Valero Energy Has a Huge Upside Price Target

A breakout could soon be at hand for the oil refiner.

Shopping for Nordstrom Stock Is a Traders Delight

JWN cut its full-year profit forecast following a weaker-than-expected holiday sales update.

Just What's Going on With AT&T and Its Charts?

The telecommunications, media and technology firm reports earnings January 25th.

Celestica Is Poised for an Upside Breakout

Here's a move aggressive traders could make now.

Halliburton May Soon Face Price Weakness

The energy sector has been a bright spot in the stock market for the past year or so but let's see what HAL's charts are telling us.

PPG Industries Is Painting a 'Shaky' Picture Ahead of Earnings

Sellers appear to be moving to a more aggressive stance on the stock.

Microsoft Faces Macro Chart Issues With Earnings on the Horizon

The technical signals of the software giant indicate that the lengthy slide in its shares likely isn't over.

Netflix Isn't Showing Much Conviction Ahead of Earnings

It might be best to wait to see where things settle out after the streaming service reports fourth-quarter results.

As Celldex Recovers, Here's My Strategy

Let's check the charts on this clinical stage drug developer.

Will J.B. Hunt Keep on Truckin' to the Upside?

Let's see what the charts are indicating.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight